Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309513612> ?p ?o ?g. }
- W4309513612 endingPage "122387" @default.
- W4309513612 startingPage "122387" @default.
- W4309513612 abstract "Vitiligo is an autoimmune disease where its current treatment strategies are lengthy in course and do not guarantee complete cure. Tofacitinib citrate (JAK inhibitor) is a potential cure of vitiligo through halting JAK-STAT pathway preventing the destruction of melanocytes. The dermato-pharmacokinetics of the prepared transethosomes (Et) and the hybridized ethosomes/nanostructured lipid carriers (Eth/NLC), namely formulations; M.E-Cr and M.E-S.M, were evaluated. In addition, in vivo studies on C57/BL6 vitiligo mouse model were conducted to confirm effectiveness of Tofacitinib citrate delivery. The results unveiled that the transethosomes (359.46 ± 11.82 nm) were suitable for dermal delivery while M.E-Cr (179.64 ± 11.16 nm), a hybrid Eth/NLC formulation, was mostly suitable for transdermal delivery. Nevertheless, another hybrid formulation, M.E-S.M (253.60 ± 14.64 nm), was apt for both dermal and transdermal delivery. The histopathology confirmed re-pigmentation of mice skin where formulations Et and M.E-S.M showed severe pigmentation compared to the control healthy and induced mice. On the other hand, M.E-Cr showed mild pigmentation. Immunohistochemical assay was performed to evaluate infiltration of CD 8+T-lymphocytes where mild infiltration was observed. However, the systemic IFN-γ was significantly reduced in case of M.E-Cr and M.E-S.M. The present work proposed potential effective formulations to improve the treatment of vitiligo with potential reduction in the total therapeutic dose, drug's side effects, and treatment costs." @default.
- W4309513612 created "2022-11-28" @default.
- W4309513612 creator A5015665201 @default.
- W4309513612 creator A5019112454 @default.
- W4309513612 creator A5045521565 @default.
- W4309513612 creator A5055059687 @default.
- W4309513612 creator A5056827706 @default.
- W4309513612 date "2022-12-01" @default.
- W4309513612 modified "2023-10-09" @default.
- W4309513612 title "The skin delivery of tofacitinib citrate using transethosomes and hybridized ethosomes/nanostructured lipid carriers for vitiligo therapy: Dermatopharmacokinetics and in vivo assays" @default.
- W4309513612 cites W1494514268 @default.
- W4309513612 cites W1598964830 @default.
- W4309513612 cites W1703796249 @default.
- W4309513612 cites W1744912403 @default.
- W4309513612 cites W1855866311 @default.
- W4309513612 cites W1977371539 @default.
- W4309513612 cites W1987202454 @default.
- W4309513612 cites W1991233586 @default.
- W4309513612 cites W1992066914 @default.
- W4309513612 cites W1997752295 @default.
- W4309513612 cites W2001432281 @default.
- W4309513612 cites W2012373901 @default.
- W4309513612 cites W2019915434 @default.
- W4309513612 cites W2022154646 @default.
- W4309513612 cites W2023252025 @default.
- W4309513612 cites W2027912711 @default.
- W4309513612 cites W2029059233 @default.
- W4309513612 cites W2054498917 @default.
- W4309513612 cites W2055989866 @default.
- W4309513612 cites W2057141276 @default.
- W4309513612 cites W2057155063 @default.
- W4309513612 cites W2058630030 @default.
- W4309513612 cites W2069384112 @default.
- W4309513612 cites W2072166430 @default.
- W4309513612 cites W2075411238 @default.
- W4309513612 cites W2078937040 @default.
- W4309513612 cites W2082941971 @default.
- W4309513612 cites W2085629163 @default.
- W4309513612 cites W2087702199 @default.
- W4309513612 cites W2089273562 @default.
- W4309513612 cites W2090572160 @default.
- W4309513612 cites W2094046366 @default.
- W4309513612 cites W2097803930 @default.
- W4309513612 cites W2097878152 @default.
- W4309513612 cites W2098494405 @default.
- W4309513612 cites W2100389865 @default.
- W4309513612 cites W2102432127 @default.
- W4309513612 cites W2103204596 @default.
- W4309513612 cites W2122398651 @default.
- W4309513612 cites W2124434163 @default.
- W4309513612 cites W2128401371 @default.
- W4309513612 cites W2131860317 @default.
- W4309513612 cites W2137175437 @default.
- W4309513612 cites W2138539732 @default.
- W4309513612 cites W2142390919 @default.
- W4309513612 cites W2145278486 @default.
- W4309513612 cites W2148860771 @default.
- W4309513612 cites W2156365652 @default.
- W4309513612 cites W2162946115 @default.
- W4309513612 cites W2288911386 @default.
- W4309513612 cites W2333886836 @default.
- W4309513612 cites W2397152727 @default.
- W4309513612 cites W2408008959 @default.
- W4309513612 cites W2408221360 @default.
- W4309513612 cites W2472029241 @default.
- W4309513612 cites W2520232911 @default.
- W4309513612 cites W2577287252 @default.
- W4309513612 cites W2580870032 @default.
- W4309513612 cites W2581509014 @default.
- W4309513612 cites W2591629615 @default.
- W4309513612 cites W2592121434 @default.
- W4309513612 cites W2595511842 @default.
- W4309513612 cites W2606324366 @default.
- W4309513612 cites W2765178824 @default.
- W4309513612 cites W2767584643 @default.
- W4309513612 cites W2794568335 @default.
- W4309513612 cites W2810808765 @default.
- W4309513612 cites W2810933275 @default.
- W4309513612 cites W2884727788 @default.
- W4309513612 cites W2886684404 @default.
- W4309513612 cites W2891117702 @default.
- W4309513612 cites W2893604676 @default.
- W4309513612 cites W2897934470 @default.
- W4309513612 cites W2902373780 @default.
- W4309513612 cites W2905490187 @default.
- W4309513612 cites W2911769840 @default.
- W4309513612 cites W2913725137 @default.
- W4309513612 cites W2915147916 @default.
- W4309513612 cites W2924047321 @default.
- W4309513612 cites W2946461346 @default.
- W4309513612 cites W2949094282 @default.
- W4309513612 cites W2949996007 @default.
- W4309513612 cites W2953465845 @default.
- W4309513612 cites W2954516785 @default.
- W4309513612 cites W2959706786 @default.
- W4309513612 cites W2989636280 @default.
- W4309513612 cites W3037262236 @default.
- W4309513612 cites W3037433849 @default.